Onkure Therapeutics, INC. (OKUR) — SEC Filings

Overview

Onkure Therapeutics, INC. (OKUR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 21, 2026: OnKure Therapeutics, Inc. filed its Annual Report to Security Holders (ARS) on April 21, 2026, for the period ending December 31, 2025. The company, located in Boulder, CO, is involved in the Pharmaceutical Preparations industry. This filing provides a summary of the company's performance and financ

Sentiment Summary

Across 41 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 37 neutral. The dominant filing sentiment for Onkure Therapeutics, INC. is neutral.

Filing Type Overview

Onkure Therapeutics, INC. (OKUR) has filed 2 4, 1 ARS, 10 8-K, 6 10-Q, 1 DEF 14A, 2 10-K, 6 SC 13G/A, 8 SC 13G, 1 S-1, 3 SC 13D/A, 1 10-K/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (41)

• OnKure Therapeutics Files 2025 Annual Report — ARS · Apr 21, 2026 Risk: medium
  OnKure Therapeutics, Inc. filed its Annual Report to Security Holders (ARS) on April 21, 2026, for the period ending December 31, 2025. The company, located in
• OnKure Therapeutics Files Form 4 — 4 · Apr 1, 2026 Risk: low
  On April 1, 2026, OnKure Therapeutics, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The filing date indicates transactions or e
• 8-K Filing — 8-K · Mar 30, 2026
• OnKure Therapeutics Insider Saccomano Files Form 4 on Ownership Change — 4 · Mar 24, 2026
  This Form 4 filing, dated March 24, 2026, indicates that Nicholas A. Saccomano, a reporting person for OnKure Therapeutics, Inc., has filed a statement of chang
• OnKure's Losses Widen Amid Increased R&D, Cash Dwindles to $70M — 10-Q · Nov 6, 2025 Risk: high
  OnKure Therapeutics, Inc. (OKUR) reported a net loss of $14.7 million for the three months ended September 30, 2025, an increase from a net loss of $11.6 millio
• OnKure's Losses Widen Amid Increased R&D Spend — 10-Q · Aug 12, 2025 Risk: high
  OnKure Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss
• 8-K Filing — 8-K · Jun 26, 2025
• OnKure Therapeutics Files 8-K on Security Holder Vote & Financials — 8-K · May 28, 2025 Risk: low
  On May 27, 2025, OnKure Therapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The c
• OnKure Therapeutics Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
  OnKure Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Reneo Pharmaceuticals, Inc. until a name change on
• OnKure Therapeutics Files Definitive Proxy Statement — DEF 14A · Apr 16, 2025 Risk: low
  OnKure Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 16, 2025, for the fiscal year ending December 31, 2025. The company, formerly
• 10-K Filing — 10-K · Mar 10, 2025
• OnKure Therapeutics Files 8-K: Corporate Details Updated — 8-K · Dec 10, 2024 Risk: low
  OnKure Therapeutics, Inc. filed an 8-K on December 10, 2024, reporting its principal executive offices located at 6707 Winchester Circle, #400, Boulder, Colorad
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• OnKure Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  OnKure Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position, including details on its equi
• SC 13G/A Filing — SC 13G/A · Oct 28, 2024
• OnKure Therapeutics Files for IPO — S-1 · Oct 23, 2024 Risk: medium
  OnKure Therapeutics, Inc. filed an S-1 form on October 23, 2024, indicating its intention to go public. The company, formerly known as Reneo Pharmaceuticals, In
• SC 13G/A Filing — SC 13G/A · Oct 23, 2024
• SC 13G/A Filing — SC 13G/A · Oct 16, 2024
• SC 13G Filing — SC 13G · Oct 11, 2024
• SC 13G Filing — SC 13G · Oct 11, 2024
• SC 13G Filing — SC 13G · Oct 11, 2024
• Carlyle Group Files 13D/A Amendment for OnKure Therapeutics — SC 13D/A · Oct 10, 2024 Risk: medium
  Carlyle Group Inc. has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of OnKure Therapeutics, Inc. as of October 10, 20
• SC 13G/A Filing — SC 13G/A · Oct 9, 2024
• SC 13G Filing — SC 13G · Oct 9, 2024
• OnKure Therapeutics Files 8-K on Asset Deal & Equity Sales — 8-K · Oct 8, 2024 Risk: medium
  On October 4, 2024, OnKure Therapeutics, Inc. (formerly Reneo Pharmaceuticals, Inc.) filed an 8-K detailing several significant events. These include the comple
• NEA 15 Amends 13D Filing for OnKure Therapeutics — SC 13D/A · Oct 8, 2024 Risk: medium
  New Enterprise Associates 15, L.P. (NEA 15) and its affiliated group, including Anthony A. Florence, Jr., Forest Baskett, Mohamad H. Makhzoumi, and Scott D. San
• Reneo Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · Oct 2, 2024 Risk: low
  Reneo Pharmaceuticals, Inc. filed an 8-K on October 2, 2024, reporting on matters submitted to a vote of its security holders as of September 26, 2024. The fili
• SC 13G Filing — SC 13G · Sep 26, 2024
• Reneo Pharmaceuticals to be Acquired by Syncona Limited — 8-K · Sep 20, 2024 Risk: medium
  Reneo Pharmaceuticals, Inc. announced on September 20, 2024, that it has entered into a definitive agreement to be acquired by Syncona Limited. The transaction
• Reneo Pharmaceuticals Announces Board and Executive Changes — 8-K · Sep 13, 2024 Risk: medium
  Reneo Pharmaceuticals, Inc. announced on September 9, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the compan
• Reneo Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  Reneo Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and operations, including detail
• SC 13G/A Filing — SC 13G/A · May 21, 2024
• Reneo Pharmaceuticals Announces Definitive Agreement, Equity Sales — 8-K · May 13, 2024 Risk: medium
  Reneo Pharmaceuticals, Inc. announced on May 10, 2024, that it entered into a Material Definitive Agreement. The filing also disclosed unregistered sales of equ
• NEA 15 Amends Reneo Pharma Stake Filing — SC 13D/A · May 8, 2024 Risk: medium
  On May 8, 2024, New Enterprise Associates 15, L.P. (NEA 15) filed an amendment to its Schedule 13D, reporting a change in beneficial ownership of Reneo Pharmace
• Reneo Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk:
  Reneo Pharmaceuticals, Inc. (OKUR) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Reneo Pharmaceuticals, Inc. filed a 10-Q report for the period e
• Reneo Pharmaceuticals Files 10-K/A Amendment — 10-K/A · Apr 26, 2024 Risk: low
  Reneo Pharmaceuticals, Inc. (OKUR) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. Reneo Pharmaceuticals, Inc. filed an amended 10-K repo
• Reneo Pharmaceuticals, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk: medium
  Reneo Pharmaceuticals, Inc. (OKUR) filed a Annual Report (10-K) with the SEC on March 28, 2024. Reneo Pharmaceuticals, Inc. filed its annual report on Form 10-K
• Reneo Pharma Reports Exit/Disposal Costs, Signals Strategic Shift — 8-K · Feb 23, 2024 Risk: medium
  Reneo Pharmaceuticals, Inc. filed an 8-K on February 23, 2024, reporting an event on February 20, 2024, related to costs associated with exit or disposal activi
• Octagon Capital Advisors Discloses 2.25M Share Stake in Reneo Pharma — SC 13G · Feb 5, 2024
  Octagon Capital Advisors LP, a Delaware-based investment firm, reported on February 5, 2024, that it beneficially owns 2,250,000 shares of Reneo Pharmaceuticals
• BML Investment Partners Takes 5.0% Stake in Reneo Pharma — SC 13G · Jan 17, 2024
  BML Investment Partners, L.P., a Delaware-based investment firm, has reported a new passive ownership stake in Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM). As of

Related Companies

ONCR · RPHM · RPH

Frequently Asked Questions